Trained immunity of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma, colon carcinoma and melanoma

Trained immunity of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma, colon carcinoma and melanoma - Trained immunity in thyroid carcinoma, colon carcinoma and melanoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53801

Enrollment

Registered

2022-01-26

Start date

2022-09-19

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colon carcinioma thyroid carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Subjects should be at least 18 years old and mentally competent -Newly diagnosed patients with TC, CC or melanoma or with newly diagnosed metastases and that are planned to receive conventional treatment by surgery

Exclusion criteria

Exclusion criteria: -Mentally incompetent -Pregnant or breastfeeding -Using medication interfering with the immune system -Reduced platelets counts or other conditions associated with an increased risk of bleeding - Severe comorbidities; other active malignancies (except for basalcel carcinoma) - Surgery of the primary tumor in the previous 4 months. -Serious psychiatric pathology -A self-reported alcohol consumption of >21 units per week

Design outcomes

Primary

Measure	Time frame
Transcriptional, epigenetic and functional signature of circulating monocytes and BM myeloid progenitors before and after in vitro exposure to trained immunity inducing agents.	—

Countries

Netherlands

Outcome results